Röckel A, Heidland A
Med Klin. 1979 Mar 16;74(11):401-7.
4 patients with hypertensive crisis (glomerulonephritis [n = 2], phaeochromocytoma [n = 1], reno-vascular hypertension [n = 1] combined with encephalopathy, showed a normalisation of blood-pressure up to 18 days during angiotensin-II-blockade with saralasin. Prior, blood pressure was treated insufficiently by intravenous diazoxide and Na-nitroprusside. Increased plasma-renin-activity and plasma levels of catecholamines pointed to an activation of the renin-angiotensin- and sympathico-adrenergic system. A trial of therapy with saralasin--especially, if blood-pressure response to diazoxide and sodium-nitroprusside is insufficient--could be indicated. Side-effects like pressor-reactions are excluded by very low priming doses (0,1 microgram/kg/min); rebound-hypertension at the end of the therapy is avoided by an overlapping therapy with renin suppressing drugs (beta-receptor blockers, clonidine, guanfacinum).
4例高血压危象患者(肾小球肾炎[n = 2]、嗜铬细胞瘤[n = 1]、肾血管性高血压[n = 1]合并脑病),在使用沙拉新进行血管紧张素II阻断治疗期间,血压在长达18天的时间内恢复正常。此前,静脉注射二氮嗪和硝普钠对血压的治疗效果不佳。血浆肾素活性增加和儿茶酚胺血浆水平升高表明肾素-血管紧张素系统和交感-肾上腺素能系统被激活。可以考虑进行沙拉新治疗试验——特别是当血压对二氮嗪和硝普钠反应不足时。极低的起始剂量(0.1微克/千克/分钟)可排除如升压反应等副作用;通过与肾素抑制药物(β受体阻滞剂、可乐定、胍法辛)重叠治疗可避免治疗结束时的反跳性高血压。